title: Withdrawal-induced delirium associated with a benzodiazepine switch: a case report.
abstract: BACKGROUND
  Introduced in the early 1960s, diazepam remains among the most frequently prescribed benzodiazepine-type sedatives and hypnotics. Patients with chronic use of short-acting benzodiazepines are frequently switched to diazepam because the accumulating, long-acting metabolite, N-desmethyl-diazepam, prevents benzodiazepine-associated withdrawal symptoms, which can occur during trough plasma levels of short-acting benzodiazepines. Although mild to moderate withdrawal symptoms are frequently observed during benzodiazepine switching to diazepam, severe medical complications associated with this treatment approach have thus far not been reported.
  
  
  METHODS
  A 64-year-old female Caucasian with major depression, alcohol dependence and benzodiazepine dependence was successfully treated for depression and, after lorazepam-assisted alcohol detoxification, was switched from lorazepam to diazepam to facilitate benzodiazepine discontinuation. Subsequent to the benzodiazepine switch, our patient unexpectedly developed an acute delirious state, which quickly remitted after re-administration of lorazepam. A newly diagnosed early form of mixed dementia, combining both vascular and Alzheimer-type lesions, was found as a likely contributing factor for the observed vulnerability to benzodiazepine-induced withdrawal symptoms.
  
  
  CONCLUSIONS
  Chronic use of benzodiazepines is common in the elderly and a switch to diazepam often precedes benzodiazepine discontinuation trials. However, contrary to common clinical practice, benzodiazepine switching to diazepam may require cross-titration with slow tapering of the first benzodiazepine to allow for the build-up of N-desmethyl-diazepam, in order to safely prevent severe withdrawal symptoms. Alternatively, long-term treatment with low doses of benzodiazepines may be considered, especially in elderly patients with chronic use of benzodiazepines and proven vulnerability to benzodiazepine-associated withdrawal symptoms.
authors: ARUD, Group of Private Outpatient Facilities for the Treatment of Substance Use and Co-occurring Disorders, Sihlhallenstrasse 30, CH-8026 Zurich, Switzerland. h_bosshart@bluewin.ch.
authors: Herbert
authors: H
authors: Bosshart
references: J Clin Psychiatry. 1985 Aug;46(8):344-5
references: 2862137
references: Lancet. 2003 May 17;361(9370):1723-9
references: 12767751
references: J Clin Psychopharmacol. 2002 Jun;22(3):285-93
references: 12006899
references: Nat Rev Neurosci. 2008 May;9(5):331-43
references: 18382465
references: Cochrane Database Syst Rev. 2006 Jan 25;(1):CD001190
references: 16437430
references: Drugs Aging. 1999 Jul;15(1):15-28
references: 10459729
references: Int J Geriatr Psychiatry. 2002 Aug;17(8):733-8
references: 12211123
references: J Neurochem. 2003 May;85(4):988-98
references: 12716430
references: J Pharmacol Exp Ther. 1989 Jul;250(1):134-40
references: 2746493
references: Curr Opin Pharmacol. 2005 Feb;5(1):47-52
references: 15661625
references: N Engl J Med. 2001 Aug 30;345(9):631-7
references: 11547716
references: Addiction. 2002 Mar;97(3):337-45
references: 11964110
references: Curr Opin Pharmacol. 2006 Feb;6(1):18-23
references: 16376150
references: Br J Psychiatry. 2002 Feb;180:144-7
references: 11823325
references: J R Coll Gen Pract. 1989 Apr;39(321):160-3
references: 2576073
references: Adv Neurol. 1983;34:487-91
references: 6131586
references: J Clin Psychiatry. 1999;60 Suppl 20:9-15
references: 10513852
references: Br J Gen Pract. 2002 Oct;52(483):805-8
references: 12392119